Étiquette : cannabinoïdes

De Cannabis Bono, François-Rodolphe Ingold et al., 2020

De Cannabis Bono François-Rodolphe INGOLD, Charlis D. KAPLAN, Christian SUEUR Annales Médico-Psychologiques, 2020, 178, 296-302 Doi : 10.16/j.amp.2020.01.018   Résumé Les usages du cannabis, en médecine et dans les traditions populaires, sont divers et anciens, ils ont été freinés depuis un siècle par la prohibition. Nous assistons depuis une trentaine d’années à un renouveau des pratiques sociales – production, distribution, usages – liées au cannabis. La découverte du système endocannabinoïde introduit un élément nouveau en faveur de l’utilisation médicale de cette plante. Les indications des cannabinoïdes en psychiatrie sont potentiellement nombreuses et demandent à être discutées. Il en va de même pour les mécanismes à l’œuvre qui restent à identifier, [...]

Lire la suite

Endocannabinoids : A Promising Impact for Traumatic Brain Injury, Lesley D. Schurman et al., 2017

Endocannabinoids : A Promising Impact for Traumatic Brain Injury Lesley D. Schurman and Aron H. Lichtman Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00069   The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous [...]

Lire la suite

IACM: Déclaration du Conseil sur la pandémie actuelle du corona virus et l’utilisation des cannabinoïdes,

IACM: Déclaration du Conseil sur la pandémie actuelle du corona virus et l'utilisation des cannabinoïdes IACM-Bulletin du 26 Mars 2020   Plusieurs études en laboratoire suggèrent que les cannabinoïdes peuvent avoir des effets antiviraux et antibactériens. Nous l’avons rapporté à plusieurs reprises dans le Bulletin de l'IACM. Cependant, il n'y a aucune preuve que des cannabinoïdes, tels que le CBD, le CBG ou le THC, ou encore des préparations de cannabis protègent contre l'infection du SRAS-CoV2 ou pourraient être utilisés pour traiter le Covid-19, la maladie produite par ce virus. Par ailleurs, rien ne prouve que l'utilisation de cannabinoïdes puisse augmenter le risque d'infection [...]

Lire la suite

IACM-Bulletin du 20 Mars 2020

IACM-Bulletin du 20 Mars 2020 IACM: 20ème Anniversaire de l'IACM IACM: Conférences IACM: Webinaires IACM: Bulletin IACM: Journaux IACM: Conseil d'administration IACM: Félicitations Un coup d'œil sur le passé IACM: 20ème Anniversaire de l'IACM Il y a 20 ans, un petit cercle de personnes a fondé l'IACM en tant qu'Association for Cannabis as Medicine, plus tard renommée Association for Cannabinoid Medicines. La 1ère conférence internationale de l'IACM sur les cannabinoïdes en médecine, qui s'est tenue à Berlin en 2001 avec l'hôpital de la Charité et l'Association médicale de Berlin, a réuni 80 participants [...]

Lire la suite

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, Andreza B. Sonego et al., 2016

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042   Highlights  Cannabidiol (CBD) attenuated haloperidol-induced catalepsy.  CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol.  CBD effects were blocked by 5-HT1A receptor antagonist.   Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]

Lire la suite

Use of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence, Madison Wright et al., 2019

Use of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence Madison Wright, Patricia Di Ciano, and Bruna Brands Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 1-6. Doi : 10.1089/can.2019.0052   Abstract Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as [...]

Lire la suite

Cannabis for pediatric epilepsy : protocol for a living systematic review, Jesse Elliott et al., 2018

Cannabis for pediatric epilepsy : protocol for a living systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Bláthnaid McCoy and George A. Wells Systematic Reviews, 2018, 7, 95 doi : 10.1186/s13643-018-0761-2   Abstract Background : Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will [...]

Lire la suite

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs, Hector Lafuente et al., 2011

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs Hector LAFUENTE, Francisco J. ALVAREZ, M. Ruth PAZOS, Antonia ALVAREZ, M. Carmen REY-SANTANO, Victoria MIELGO, Xabier MURGIA-ESTEVE, Enrique HILARIO, and Jose MARTINEZ-ORGADO Pediatric Research, 2011, 70, 272–277. ABSTRACT : Newborn piglets exposed to acute hypoxia-ischemia (HI) received i.v. cannabidiol (HI CBD) or vehicle (HI VEH). In HI VEH, 72 h post-HI brain activity as assessed by amplitudeintegrated EEG (aEEG) had only recovered to 42 9% of baseline, near-infrared spectroscopy (NIRS) parameters remained lower than normal, and neurobehavioral performance was abnormal (27.8 2.3 points, normal 36). [...]

Lire la suite

Cannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System, Audrey Lefebvre, 2016

Cannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System Audrey Lefebvre wakeup-world.com/2016/03/20/cannabis-as-medicine-how-cbd-cannabidiol-benefits-the-human-brainand-nervous-system/   Cannabidiol (CBD) is an active cannabinoid found in cannabis which, unlike THC (tetrahydro-cannabinol), does not produce a psychoactive effect in the brain. For this reason, CBD has become a primary focus of medicinal cannabis studies. CBD has been found to have a wide range of benefits, including lowering blood sugar levels, promoting bone growth, and importantly, protecting the human brain and nervous system from degeneration. How CBD Protects the Nervous System The nervous system is comprised of two main parts: the peripheral nervous system, which includes the nerves and ganglia on [...]

Lire la suite